Viewing Study NCT02106351


Ignite Creation Date: 2025-12-24 @ 11:45 PM
Ignite Modification Date: 2026-02-20 @ 12:35 PM
Study NCT ID: NCT02106351
Status: COMPLETED
Last Update Posted: 2022-09-28
First Post: 2014-04-03
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Sponsor: Ipsen
Organization:

Study Overview

Official Title: A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT® Used In The Treatment Of Upper Limb Spasticity In Children
Status: COMPLETED
Status Verified Date: 2022-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PUL
Brief Summary: The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport used in the treatment of upper limb spasticity (altered skeletal muscle performance) in children with cerebral palsy (CP).
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2010-021817-22 EUDRACT_NUMBER None View